Monte Rosa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
On December 8, 2023, Owen Wallace, our Chief Scientific Officer, entered into a trading plan pursuant to Rule 10b5-1 of the Exchange Act. Mr. Wallace's Rule 10b5-1 trading plan provides for the sale from time to time of a maximum of 100,000 shares of our common stock pursuant to the terms of the plan. Mr. Wallace's Rule 10b5-1 trading plan expires on March 1, 2025, or earlier if all transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
During the fiscal quarter ended December 31, 2023, other than described in the statement above, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted, terminated or modified a Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading agreement (as defined in Item 408(c) of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.